119 related articles for article (PubMed ID: 26334457)
21. Accuracies of fecal calprotectin, lactoferrin, M2-pyruvate kinase, neopterin and zonulin to predict the response to infliximab in ulcerative colitis.
Frin AC; Filippi J; Boschetti G; Flourie B; Drai J; Ferrari P; Hebuterne X; Nancey S
Dig Liver Dis; 2017 Jan; 49(1):11-16. PubMed ID: 27693318
[TBL] [Abstract][Full Text] [Related]
22. Infliximab for ulcerative colitis.
Actis GC
Am J Gastroenterol; 2003 Mar; 98(3):709. PubMed ID: 12650824
[No Abstract] [Full Text] [Related]
23. Changes in cytokine profile may predict therapeutic efficacy of infliximab in patients with ulcerative colitis.
Sato S; Chiba T; Nakamura S; Matsumoto T
J Gastroenterol Hepatol; 2015 Oct; 30(10):1467-72. PubMed ID: 25968585
[TBL] [Abstract][Full Text] [Related]
24. Long-Term Outcome of Patients with Ulcerative Colitis and Primary Non-response to Infliximab.
Papamichael K; Rivals-Lerebours O; Billiet T; Vande Casteele N; Gils A; Ferrante M; Van Assche G; Rutgeerts PJ; Mantzaris GJ; Peyrin-Biroulet L; Vermeire S
J Crohns Colitis; 2016 Sep; 10(9):1015-23. PubMed ID: 27022161
[TBL] [Abstract][Full Text] [Related]
25. Infliximab for severe ulcerative colitis and subsequent SARS-CoV-2 pneumonia: a stone for two birds.
Bezzio C; Manes G; Bini F; Pellegrini L; Saibeni S
Gut; 2021 Mar; 70(3):623-624. PubMed ID: 32554621
[No Abstract] [Full Text] [Related]
26. Tofacitinib for the treatment of acute severe ulcerative colitis refractory to infliximab.
Fortuny Bauzá M; Cañete Pizarro F; Calm Salvans A; Calafat Sard M; Domènech Morral E
Gastroenterol Hepatol; 2022 Apr; 45 Suppl 1():11-12. PubMed ID: 34118322
[No Abstract] [Full Text] [Related]
27. Normalization of mucosal tumor necrosis factor-α: A new criterion for discontinuing infliximab therapy in ulcerative colitis.
Olsen T; Rismo R; Gundersen MD; Paulssen EJ; Johnsen K; Kvamme JM; Goll R; Florholmen J
Cytokine; 2016 Mar; 79():90-5. PubMed ID: 26775117
[TBL] [Abstract][Full Text] [Related]
28. Sacroileitis and peripheral arthropathy associated with ulcerative colitis: effect of infliximab on both articular and intestinal symptoms.
Lupascu A; Armuzzi A; De Pascalis B; Carloni E; Lauritano EC; Gasbarrini A; Pola P; Gasbarrini A
Dig Liver Dis; 2004 Jun; 36(6):423-5. PubMed ID: 15248384
[TBL] [Abstract][Full Text] [Related]
29. Infliximab in the treatment of steroid-dependent ulcerative colitis.
Armuzzi A; De Pascalis B; Lupascu A; Fedeli P; Leo D; Mentella MC; Vincenti F; Melina D; Gasbarrini G; Pola P; Gasbarrini A
Eur Rev Med Pharmacol Sci; 2004; 8(5):231-3. PubMed ID: 15638236
[TBL] [Abstract][Full Text] [Related]
30. Fecal Calprotectin as Predictor of Relapse in Patients With Inflammatory Bowel Disease Under Maintenance Infliximab Therapy.
Ferreiro-Iglesias R; Barreiro-de Acosta M; Otero Santiago M; Lorenzo Gonzalez A; Alonso de la Peña C; Benitez Estevez AJ; Dominguez-Muñoz JE
J Clin Gastroenterol; 2016 Feb; 50(2):147-51. PubMed ID: 25811118
[TBL] [Abstract][Full Text] [Related]
31. Infliximab therapy for ulcerative colitis: many unanswered questions.
Present DH
Am J Gastroenterol; 2001 Aug; 96(8):2294-6. PubMed ID: 11513164
[No Abstract] [Full Text] [Related]
32. Infliximab rescue therapy in ulcerative colitis, and the effect on subsequent colectomy rates.
Halpin SJ; Hamlin PJ; Ford AC
Aliment Pharmacol Ther; 2010 Nov; 32(10):1294-5. PubMed ID: 20955450
[No Abstract] [Full Text] [Related]
33. Higher Rates of Dose Optimisation for Infliximab Responders in Ulcerative Colitis than in Crohn's disease.
O'Donnell S; Stempak JM; Steinhart AH; Silverberg MS
J Crohns Colitis; 2015 Oct; 9(10):830-6. PubMed ID: 26116556
[TBL] [Abstract][Full Text] [Related]
34. Accelerated ustekinumab dosing as rescue therapy in acute severe ulcerative colitis.
Affendi NANM; Ooi CJ; Hilmi IN
J Gastrointestin Liver Dis; 2022 Dec; 31(4):478-479. PubMed ID: 36535053
[No Abstract] [Full Text] [Related]
35. Histological healing after infliximab induction therapy in children with ulcerative colitis.
Wiernicka A; Szymanska S; Cielecka-Kuszyk J; Dadalski M; Kierkus J
World J Gastroenterol; 2015 Oct; 21(37):10654-61. PubMed ID: 26457025
[TBL] [Abstract][Full Text] [Related]
36. Appendiceal Orifice Inflammation in Severe Ulcerative Colitis and Its Resolution With Infliximab and Plant-based Diet as First-line Therapy.
Chiba M; Ishii H; Sageshima M; Iwabuchi A
Inflamm Bowel Dis; 2021 Oct; 27(11):e138-e139. PubMed ID: 34291790
[TBL] [Abstract][Full Text] [Related]
37. Takayasu arteritis developing during treatment of ulcerative colitis with infliximab.
Horai Y; Satoru O; Lapalme-Remis S; Sumiyoshi R; Nakashima Y; Suzuki T; Okada A; Kawashiri SY; Ichinose K; Tamai M; Yamasaki S; Nakamura H; Takeshima F; Origuchi T; Kawakami A
Mod Rheumatol; 2013 May; 23(3):572-6. PubMed ID: 22718488
[TBL] [Abstract][Full Text] [Related]
38. Infliximab rescue therapy in steroid-refractory ulcerative colitis: is more really more?
Molnár T; Farkas K; Szepes Z; Nagy F; Wittmann T
Aliment Pharmacol Ther; 2011 Feb; 33(3):412-3. PubMed ID: 21198699
[No Abstract] [Full Text] [Related]
39. Infliximab for the treatment of ulcerative colitis: outcomes in Oxford from 2000 to 2006.
Jakobovits SL; Jewell DP; Travis SP
Aliment Pharmacol Ther; 2007 May; 25(9):1055-60. PubMed ID: 17439506
[TBL] [Abstract][Full Text] [Related]
40. Using Therapeutic Drug Monitoring to Identify Variable Infliximab Metabolism in an Individual Patient With Ulcerative Colitis.
Stein BN; Pellish RS; Thompson KD; Baptista V; Siegel CA
J Clin Gastroenterol; 2016 Jan; 50(1):66-8. PubMed ID: 26191643
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
